To undertake a greater range of scientific research and development for pharmaceuticals across a broader range of activities
To undertake a greater range of scientific research and development for pharmaceuticals across a broader range of activities, Syngene International, India’s contract research organization, has announced that it has expanded its ongoing collaboration with Bristol-Myers Squibb.
The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026.
Syngene and Bristol-Myers Squibb have worked together since 1998. The research campus, known as Biocon BMS Research Center (BBRC), Syngene’s first dedicated R&D Center, was established in 2007, which was subsequently renewed through 2020 and now has been further extended through 2026.
It is the largest research and development facility for Bristol-Myers Squibb outside of the United States and plays an integral part within their global research and development network.
Since its inception, BBRC has contributed to the discovery and pre-clinical development of numerous drug candidates for further study, as well as generated data that has led to multiple patent filings around the world.
It has also played a key role in reducing the time and costs associated with advancing new compounds to first-in-human studies for Bristol-Myers Squibb.
As part of the expansion, Syngene will set up a new dedicated facility